a Division of Surgical Oncology , National Cancer Centre Singapore , Singapore.
Int J Hyperthermia. 2018 Aug;34(5):551-558. doi: 10.1080/02656736.2017.1387939. Epub 2017 Oct 30.
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) improve survival in selected patients with peritoneal metastases. However, only some patients who are potentially eligible for the procedure are considered and referred to the appropriate surgical department. By studying the trends of patients being considered for CRS and HIPEC in our centre, we hope to better understand the demographics of our patient cohort and the attitudes of physicians involved towards CRS and HIPEC.
Patients who were presented and discussed at our institution's multidisciplinary tumour board (MDTB) for consideration of CRS and HIPEC, between 5 January 2011 and 16 December 2015, were identified from the institutional database and included in the study. Patient demographics and clinico-pathological data were retrospectively collected from electronic records and clinical charts.
A total of 407 patients were presented at the MDTB for consideration of CRS and HIPEC. Referrals were most commonly from oncology-related departments (65.8%, n = 268). This was followed by referrals from other hospitals (15.0%, n = 61), overseas self-referrals (12.0%, n = 49) and non-oncologic departments within the same institution (7.1%, n = 29). Referrals made by oncology-related departments and overseas self-referrals showed an increasing trend over the years. Of the patients discussed, 197 patients (48.4%) were recommended for CRS and HIPEC, and 134 (68.0%) successfully underwent the procedure.
There is growing acceptance of CRS and HIPEC in patients and oncologic-related departments. However, consideration of this procedure as a treatment option remains low in non-oncologic departments. Dissemination of information and well-defined clinical recommendations may help physicians identify and select potentially eligible patients for consideration of CRS and HIPEC.
细胞减灭术（CRS）和腹腔内热灌注化疗（HIPEC）可改善特定腹膜转移患者的生存。然而，只有部分符合手术条件的患者被认为适合接受该手术，并被转诊至相应的外科科室。通过研究本中心接受 CRS 和 HIPEC 治疗的患者趋势，我们希望更好地了解患者群体的人口统计学特征，以及参与医生对 CRS 和 HIPEC 的态度。
我们从机构数据库中确定了 2011 年 1 月 5 日至 2015 年 12 月 16 日在本机构多学科肿瘤委员会（MDTB）提出并讨论了接受 CRS 和 HIPEC 治疗的患者。从电子病历和临床图表中回顾性收集患者的人口统计学和临床病理数据。
共有 407 名患者在 MDTB 提出接受 CRS 和 HIPEC 治疗。最常见的转诊科室是肿瘤相关科室（65.8%，n=268），其次是其他医院（15.0%，n=61）、海外自行转诊（12.0%，n=49）和同一机构内的非肿瘤科室（7.1%，n=29）。肿瘤相关科室和海外自行转诊的转诊呈逐年上升趋势。在讨论的患者中，197 名患者（48.4%）被推荐接受 CRS 和 HIPEC，其中 134 名（68.0%）成功接受了该手术。
患者和肿瘤相关科室对 CRS 和 HIPEC 的接受度越来越高。然而，非肿瘤科室将该手术作为治疗选择的考虑仍然较低。信息传播和明确的临床推荐可能有助于医生识别和选择潜在适合接受 CRS 和 HIPEC 治疗的患者。
Zotero 插件